Chugai ponies up $1B+ to combine R&D in Yokohama by Amirah Al Idrus Wednesday, May 22, 2019 Chugai Pharmaceuticals is shelling out ¥127.3 billion on a new R&D site in Yokohama, where it will combine the work of two research labs in nearby cities.
Alexion’s Soliris follow-up clears trial in second rare disease by Phil Taylor Monday, January 28, 2019 Smarting from a patent defeat for Soliris in Europe, Alexion has dulled the pain with a phase 3 readout for follow-up Ultomiris.
Apellis says timeline still on track for stalled eye drug by Phil Taylor Thursday, December 20, 2018 After halting phase 3 trials for its APL-2 drug in geographic atrophy on safety concerns, Apellis says it will restart the program next year.
Chugai preps filings for Soliris rival in rare disease by Phil Taylor Wednesday, December 19, 2018 Chugai has the phase 3 data it needs to file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum disorder next year.
Ra Pharma files $100M round as Soliris rival clears ph2 trial by Phil Taylor Tuesday, December 11, 2018 A phase 2 win for its lead drug in myasthenia gravis has Ra Pharma pressing the button on a $115 million public funding round.
Alexion snags option to buy neurodegeneration startup Complement by Nick Paul Taylor Monday, June 11, 2018 The deal will see Alexion work with Complement to take a C6 complement inhibitor through phase 1b and decide whether to execute a takeover.
Alexion’s Soliris successor clears phase 3, teeing up filings by Nick Paul Taylor Friday, April 27, 2018 The success positions Alexion to file for approval and shield itself from an anticipated assault on its paroxysmal nocturnal hemoglobinuria franchise.
Alexion hits endpoints in ALXN1210-Soliris test as it plots filings by Ben Adams Thursday, March 15, 2018 Alexion hit key endpoints for its experimental phase 3 drug ALXN1210 in patients with a life-threatening ultrarare blood disorder.
Alexion cost cutting is 'all about building pipeline' by Phil Taylor Tuesday, September 12, 2017 Alexion is slashing its workforce by around 20% and closing sites in a bid to save $250 million a year, with R&D bearing the brunt.
Apellis sets up another phase 3 program for lead drug by Phil Taylor Friday, August 25, 2017 Apellis reported positive midstage data for its lead candidate in age-related macular degeneration shortly after a $60 million series E raise.
